阿托伐他汀钙片治疗非创伤性硬膜下血肿的临床研究  

Clinical trial of atorvastatin calcium tablets in the treatment of nontraumatic subdural hematoma

作　　者：杨开华[1] 余云湖[1] 冉启山[1] 文远超[1] 李航[1] 付晓红 

机构地区：[1]遵义医学院第三附属医院神经外科,贵州遵义563000

出　　处：《中国临床药理学杂志》2017年第18期1751-1753,共3页The Chinese Journal of Clinical Pharmacology

基　　金：贵州省科技计划基金资助项目[SY(2012)3118]

摘　　要：目的观察阿托伐他汀钙片治疗非创伤性硬膜下血肿的临床疗效及安全性。方法将52例非创伤性硬膜下血肿患者随机分为对照组26例和试验组26例。对照组予以钻孔引流术治疗,封闭骨孔并进行闭式引流2~3 d;试验组在对照组治疗的基础上,予以阿托伐他汀钙片20 mg,qd,口服,连续用药28 d。比较2组患者的临床疗效、血清中超氧化物歧化酶(SOD)、丙二醛(MDA)水平、复发率,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为84.62%(22/26例)和57.69%(15/26例),差异有统计学意义(P<0.05)。治疗后,对照组和试验组的SOD分别为(115.29±13.34)和(128.39±14.29)U·m L^(-1),MDA分别为(19.83±2.43)和(15.40±1.67)nmol·m L^(-1),复发率分别为26.92%(7/26例)和0(0/26例),差异均有统计学意义(均P<0.05)。试验组发生的药物不良反应有血肿量增加和感染,对照组发生的药物不良反应有颅内气肿、血肿量增加、感染、肝功能异常、脑损伤,试验组和对照组的药物不良反应发生率分别为7.69%和34.62%,差异有统计学意义(P<0.05)。结论阿托伐他汀钙片治疗非创伤性硬膜下血肿的临床疗效显著,且药物不良反应发生率和复发率均较低。Objective To observe the clinical efficacy and safety of atorvastatin calcium tablets in the treatment of nontraumatic subdural hematoma. Methods A total of 52 patients with nontraumatic subdural hematoma were randomly divided into control group and treatment group with 26 cases per group. Control group was given the treatment of drilling and drainage for 2-3 days. Treatment group received atorvastatin calcium 20 mg,qd,oral for 28 days,on the basis of control group. The clinical efficacy,serum superoxide dismutase（ SOD）,malondialdehyde（ MDA）,recurrence rate,and adverse drug reaction were compared between the two groups. Results After treatment,the total effective rates in treatment and control groups were 84. 62%（ 22/26 cases） and57. 69%（ 15/26 cases） with significant difference（ P〈0. 05）. After treatment,the SOD in control and treatment groups were（ 115. 29 ±13. 34）,（ 128. 39 ± 14. 29） U · mL^（-1）; MDA were（ 19. 83 ± 2. 43）,（ 15. 40 ± 1. 67） nmol·mL^（-1）; recurrence rates were 26. 92%（ 7/26cases） and 0（ 0/26 cases）,the differences were statistically significant（ all P〈0. 05）. The adverse drug reactions in treatment groupwere based on increased hematoma volume and infection,which in control group were based on intracranial emphysema,increased hematoma volume,infection,abnormal liver function and brain damage. The incidences of adverse drug reactions in treatment and control groups were 7. 69% and 34. 62% with significant difference（ P〈0. 05）.Conclusion Atorvastatin calcium tablets have a definitive clinical efficacy and safety in the treatment of nontraumatic subdural hematoma.

关 键 词：阿托伐他汀钙片 非创伤性硬膜下血肿 安全性 

分 类 号：R972.6[医药卫生—药品]